Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human therapeutics. With a market cap of $176.4 billion, the company focuses on human therapeutics and develops novel medicines based on cellular and molecular biology. The drug manufacturing giant is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. Ahead of the event, analysts expect AMGN to report a profit of $4.74 per share on a diluted basis, down 10.7% from ...